Dynavax Technologies Corporation (DVAX)

NASDAQ: DVAX · IEX Real-Time Price · USD
11.84
+0.06 (0.51%)
At close: Jan 27, 2023, 4:00 PM
11.71
-0.13 (-1.10%)
After-hours: Jan 27, 2023, 7:59 PM EST
0.51%
Market Cap 1.51B
Revenue (ttm) 733.26M
Net Income (ttm) 320.63M
Shares Out 127.59M
EPS (ttm) 2.29
PE Ratio 5.17
Forward PE 6.36
Dividend n/a
Ex-Dividend Date n/a
Volume 1,914,456
Open 11.81
Previous Close 11.78
Day's Range 11.71 - 12.00
52-Week Range 7.26 - 17.48
Beta 1.43
Analysts Buy
Price Target 23.66 (+99.83%)
Earnings Date Feb 27, 2023

About DVAX

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.... [Read more]

Sector Healthcare
CEO Ryan Spencer
Employees 311
Stock Exchange NASDAQ
Ticker Symbol DVAX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $23.66, which is an increase of 99.83% from the latest price.

Price Target
$23.66
(99.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 103.22%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 103.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionab...

1 day ago - Zacks Investment Research

Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023

-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, br...

1 week ago - GlobeNewsWire

The 7 Most Undervalued Long-Term Stocks to Buy in January

With 2022 in the rearview mirror, it's time to hunt for solid, undervalued long-term stocks to buy. First, it's essential to define what is meant by long-term.

Other symbols: AMRATKREOGLPROLRCXVGR
1 week ago - InvestorPlace

Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results

Preliminary full year 2022 HEPLISAV-B® vaccine Net Product Revenue of approximately $126 million, representing 104% growth compared to 2021 Preliminary full year CpG 1018® adjuvant Net Product Revenue...

2 weeks ago - PRNewsWire

7 Cheap Stocks That Wall Street Analysts Still Love

In 2022, the S&P 500 had its worst year since 2008, with a total return of -18.11%, nearly 47 percentage points worse than in 2021. But it could have been much worse.

3 weeks ago - InvestorPlace

Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine

Saint- Herb lain (France) , December 30 , 202 2 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further heterologous booster data from an exploratory, sm...

Other symbols: VALN
1 month ago - GlobeNewsWire

Our 7 Top Small-Cap Stock Picks for 2023

One of the more fun assignments at InvestorPlace is selecting the top small-cap stock picks for 2023. In this case, I've been chosen to provide readers with seven options for next year.

Other symbols: CALMCVCOHCCKLICMMIWIRE
1 month ago - InvestorPlace

Clover's Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases

-- The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household memb...

2 months ago - GlobeNewsWire

Dynavax to Present at Two Upcoming Investor Conferences

EMERYVILLE, Calif. , Nov. 9, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...

2 months ago - PRNewsWire

Surging Earnings Estimates Signal Upside for Dynavax Technologies (DVAX) Stock

Dynavax Technologies (DVAX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

2 months ago - Zacks Investment Research

Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

2 months ago - Zacks Investment Research

Dynavax Technologies (DVAX) Recently Broke Out Above the 200-Day Moving Average

When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?

2 months ago - Zacks Investment Research

Wall Street Analysts See a 154% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?

The consensus price target hints at a 154.4% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn...

2 months ago - Zacks Investment Research

Best Value Stocks to Buy for November 7th

HDSN, CWBC and DVAX made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2022.

Other symbols: CWBCHDSN
2 months ago - Zacks Investment Research

Dynavax Technologies (DVAX) Beats Q3 Earnings and Revenue Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 30.30% and 11.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc...

3 months ago - Zacks Investment Research

Dynavax Reports Third Quarter 2022 Financial Results

Q3 2022 total revenue of $167.7 million, up 55% from $108.3 million for Q3 2021 HEPLISAV-B ®  vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 CpG 1018 ® adjuvant ne...

3 months ago - PRNewsWire

Dynavax Technologies (DVAX) Recently Broke Out Above the 50-Day Moving Average

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

3 months ago - Zacks Investment Research

Dynavax Technologies (DVAX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

3 months ago - Zacks Investment Research

Does Dynavax Technologies (DVAX) Have the Potential to Rally 210% as Wall Street Analysts Expect?

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 210.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

3 months ago - Zacks Investment Research

Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022

EMERYVILLE, Calif. , Oct. 20, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil...

3 months ago - PRNewsWire

Should Value Investors Buy Dynavax Technologies (DVAX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

3 months ago - Zacks Investment Research

Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference

EMERYVILLE, Calif. , Oct. 14, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...

3 months ago - PRNewsWire

3 Under-the-Radar Small-Cap Stocks With 100% Upside Potential

If under-the-radar small-cap stocks are your jam, I've got three selections from the S&P SmallCap 600 that might be right up your alley. The small-cap index is down 20.3% year to date.

Other symbols: OXMPFBC
3 months ago - InvestorPlace

Clover Provides Update on 2022 Corporate Milestones

-- Significant progress made on regulatory submissions to the China NMPA, the EMA, and the WHO for Clover's lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), with completion anticipated in Q4...

3 months ago - GlobeNewsWire

Bet on These 4 Biotech Stocks With Bright Prospects

New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well am...

Other symbols: AGENCVACIMCR
4 months ago - Zacks Investment Research